Skip to main content

Table 4 Adverse events reported in ≥ 2% of subjects in each groupa

From: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A

Eventb

High-dose PXT3003

Low-dose PXT3003

Placebo

pc

N = 113

N = 109

N = 101

Nausea

6 (5.3)

7 (6.4)

3 (3.0)

0.502

Diarrhea

6 (5.3)

3 (2.8)

5 (5.0)

0.620

Headache

6 (5.3)

6 (5.5)

3 (3.0)

0.639

Dry mouth

3 (2.7)

2 (1.8)

4 (4.0)

0.642

Dizziness

3 (2.7)

4 (3.7)

1 (1.0)

0.496

Muscle spasms

3 (2.7)

nil

3 (3.0)

0.223

Nasopharyngitis

3 (2.7)

4 (3.7)

5 (5.0)

0.662

Dyspepsia

2 (1.8)

1 (0.9)

2 (2.0)

0.868

Fatigue

1 (0.9)

6 (5.5)

4 (4.0)

0.132

Somnolence

1 (0.9)

5 (4.6)

1 (1.0)

0.185

Constipation

1 (0.9)

3 (2.8)

1 (1.0)

0.536

Arthralgia

1 (0.9)

3 (2.8)

2 (2.0)

0.608

Asthenia

1 (0.9)

1 (0.9)

2 (2.0)

0.693

Tinnitus

1 (0.9)

1 (0.9)

2 (2.0)

0.693

Abdominal pain

1 (0.9)

Nil

2 (2.0)

0.311

Weight increased

Nil

Nil

3 (3.0)

0.030

  1. aData reported as number of subjects (%)
  2. bCoded according to preferred terms in the Medical Dictionary for Regulatory Activities, version 18.1 or later
  3. cValues calculated using Fisher’s exact test. Please note that there is no correction for multiple testing, thus no control of type I error rate